@Yale_CRIT


Yale_CRIT
@Yale_CRIT -
Sep 29
Check out our @Yale_CRIT co-Director's 🧵below on how today's @OIGatHHS report on the impacts of confirmatory trial delays for @US_FDA accelerated approval drugs including financial costs to @CMSGov highlights key issues our team & others have studied signaling a need for reform. https://t.co/yTYlopRJ0J
Yale_CRIT
@Yale_CRIT -
Sep 28
Re-upping this piece from @SkydelJ @jsross119 & @reshmagar on why accelerated approval reforms are still needed despite not being in this year's @US_FDA user fee bill & their @JAMAHealthForum study findings of high @CMSGov spending for unproven AA drugs: https://t.co/XrGL08nfZg https://t.co/STN4Uje7DV
Yale_CRIT
@Yale_CRIT -
Sep 28
Wanting to: ✅ delve into the evidence behind @US_FDA drug and device approvals? ✅ inform policy recommendations to ensure patients have access to truly safe & effective treatments? ✅ work with an interdisciplinary team of researchers/mentors? Join us! https://t.co/4bUQG0BDQF https://t.co/AivpEnZRHQ
Yale_CRIT
@Yale_CRIT -
Sep 20
ICYMI: @Yale_CRIT Directors @jsross119 & @reshmagar were in the @nytimes last week with collaborators @UCSF's Drs. Sanket Dhruva & @TheWonkologist on how user fees have led to a "devil's bargain" between @US_FDA & industry the agency is meant to regulate: https://t.co/xg7fqzkkMb

CRIT Program Mission Statement


To promote health by improving the integrity and transparency of biomedical and clinical research

CRIT Program


The Collaboration for Research Integrity and Transparency (CRIT) is an inter-disciplinary initiative with a goal to enhance the quality and transparency of the research base for medical products. While no longer actively grant funded, CRIT continues to pursue selective research, advocacy, and litigation to ensure that the clinical evidence that supports and informs our understanding of the safety and effectiveness of pharmaceuticals, medical devices, and other medical products is accurate, comprehensive, accessible, and reliable. The lack of transparency and integrity in clinical research has had serious consequences for patient and clinicians. Current legal structures and research practices are not adequate and efforts to understand and improve clinical research transparency and reporting are needed.

By influencing stakeholders engaged in the clinical research process and in translating these findings for clinical care, CRIT focused and magnified the impact of our and others’ scholarship, policy analysis and legal action, advancing the field of research integrity, open science, and informing public discourse.

CRIT aimed to

  • Achieve a legal and regulatory environment that promotes rigorous clinical research and supports regulatory and clinical decisions that are grounded in high-quality research and accessible data and results.
  • Strengthen the integrity of research of medical products by ensuring that data is both rigorous and reliable, and by facilitating public access to and independent analysis of clinical trial data and results.
  • Conduct legal, public health and health policy research that identifies strengths and weakness of our existing system for facilitating evidence generation and transparency, and developing and evaluating alternative approaches
  • Provide the public and key policymakers with tools that enhance and facilitate open access to data, research results, and other relevant information about medical products.

Funding